Clinic
Huntington Hospital Association
Huntington Hospital Association was paid $9.83M by Medicaid between Jan 2018 and Dec 2024, across 118 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoHUNTINGTON HOSPITAL ASSOCIATION
HUNTINGTON, NY 11743
HUNTINGTON, NY 11743
33aNPI1508845322assigned 01/11/2006
33bProvider typeEnd-Stage Renal Disease (ESRD) Treatment Clinic/Center
28Total paid$9.83M
24GClaims236,728
24DCodes billed118
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other End-Stage Renal Disease (ESRD) Treatment Clinic/Center providers in New York
Rank by total paid#12 of 231
Median peer was paid$774K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CUSACK, MICHELE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,055 | $161K | |
| 2019 | 15,896 | $731K | |
| 2020 | 35,742 | $2.01M | |
| 2021 | 57,791 | $2.50M | |
| 2022 | 46,048 | $1.67M | |
| 2023 | 44,041 | $1.55M | |
| 2024incomplete | 33,155 | $1.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 13,347 | 12,766 | $2.47M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 10,897 | 10,352 | $1.88M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 6,192 | 5,788 | $1.06M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.2% | 7,133 | 6,403 | $611K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.9% | 3,135 | 3,059 | $576K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 2,224 | 2,160 | $356K |
| 36415 | Collection of venous blood by venipuncture | 3.6% | 27,496 | 17,008 | $349K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.5% | 2,495 | 2,376 | $349K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 2,260 | 2,217 | $328K |
| 80053 | Comprehensive metabolic panel | 2.4% | 13,583 | 12,545 | $234K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 936 | 906 | $156K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,886 | 5,514 | $98K |
106 more codes
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,047 | $88K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 120 | $78K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,616 | $77K |
| 86901 | <1% | 3,766 | $73K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,528 | $73K |
| 86850 | <1% | 3,762 | $71K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,536 | $67K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,703 | $65K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 119 | $58K |
| 86900 | <1% | 3,763 | $57K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,293 | $52K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,140 | $49K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,602 | $42K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,676 | $41K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 884 | $40K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,840 | $29K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 814 | $27K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 740 | $25K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 211 | $25K |
| 85730 | <1% | 4,363 | $23K | |
| 81001 | <1% | 6,193 | $23K | |
| 93975 | <1% | 76 | $17K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 138 | $17K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 97 | $15K |
| 84702 | <1% | 2,920 | $15K | |
| 59025 | Fetal non-stress test | <1% | 110 | $14K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,447 | $14K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,760 | $13K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,319 | $13K |
| 85610 | <1% | 3,952 | $12K | |
| 0225U | <1% | 1,614 | $12K | |
| 83880 | <1% | 733 | $11K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 626 | $11K |
| J3490 | Unclassified drugs | <1% | 2,837 | $10K |
| 87631 | <1% | 225 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,030 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 978 | $8K |
| 81025 | <1% | 2,138 | $6K | |
| 88304 | <1% | 163 | $6K | |
| 83690 | <1% | 3,679 | $6K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,171 | $6K |
| 81003 | <1% | 2,256 | $4K | |
| 36000 | <1% | 306 | $4K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 29 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 70 | $2K |
| 85027 | <1% | 733 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 196 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $2K |
| 82962 | <1% | 1,712 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,033 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,285 | $2K |
| 84484 | <1% | 3,292 | $2K | |
| 90715 | <1% | 97 | $2K | |
| C9399 | Unclassified drugs or biologicals | <1% | 25 | $2K |
| 88312 | <1% | 79 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 104 | $2K |
| 87040 | <1% | 915 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 828 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,708 | $1K |
| 83605 | <1% | 1,193 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,483 | $1K |
| 83735 | <1% | 1,867 | $895.25 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,077 | $791.95 |
| 96376 | <1% | 70 | $776.34 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 502 | $755.23 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 29 | $718.15 |
| 85379 | <1% | 908 | $714.28 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 491 | $703.95 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 37 | $522.82 |
| 73110 | <1% | 33 | $478.74 | |
| 82803 | <1% | 42 | $465.97 | |
| 73562 | <1% | 39 | $432.75 | |
| 88307 | <1% | 12 | $430.24 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 265 | $409.63 |
| 87486 | <1% | 29 | $371.16 | |
| 73630 | <1% | 87 | $367.51 | |
| 87081 | <1% | 406 | $338.47 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 514 | $334.20 |
| 86703 | <1% | 52 | $333.32 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 127 | $308.21 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 560 | $293.25 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 114 | $281.19 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 228 | $272.21 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 29 | $270.45 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 121 | $267.49 |
| 87581 | <1% | 29 | $255.10 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 250 | $247.23 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 111 | $231.37 |
| 87186 | <1% | 170 | $228.05 | |
| 86803 | <1% | 65 | $223.87 | |
| 82040 | <1% | 37 | $187.39 | |
| 73610 | <1% | 85 | $167.28 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $116.62 |
| Q3014 | Telehealth originating site facility fee | <1% | 13 | $106.25 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 245 | $98.44 |
| 84100 | <1% | 32 | $87.47 | |
| 73030 | <1% | 12 | $55.11 | |
| 87077 | <1% | 64 | $48.48 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 53 | $39.09 |
| 73130 | <1% | 57 | $20.63 | |
| 76376 | 0% | 27 | $0.00 | |
| 88313 | 0% | 12 | $0.00 | |
| 73590 | 0% | 14 | $0.00 | |
| 99080 | 0% | 89 | $0.00 | |
| 82550 | 0% | 12 | $0.00 | |
| 73090 | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCUSACK, MICHELE (SENIOR VICE PRESIDENT & CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.